The spectacular failureofBristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo in the CheckMate 026 first-line lung cancer study raises questions about whether the right cut-off levels for the PD-L1 expression biomarker were used.
Bristol reported that the drug missed the primary progression-free-survival endpoint in the first-line CheckMate 026 study on Aug. 5, prompting a dive that had the company closing down 15.99% and competitors up